glycyrrhizic acid has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berg, D; Forrester, JV; Gasser, T; Hobert, MA; Maetzler, W; Martin, HL; Rattay, TW; Riedel, G; Santoro, M; Stathakos, P; Teismann, P; Tracey, KJ | 1 |
| Gao, D; Gao, X; Jiang, X; Jin, M; Liu, K; Paudel, YN; Ren, Q; Shang, X; Sheng, W; Zhang, P; Zhang, X | 1 |
2 other study(ies) available for glycyrrhizic acid and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Cell Death; Disease Models, Animal; Dopaminergic Neurons; Female; Glycyrrhizic Acid; HMGB1 Protein; Humans; Male; Mice, Inbred C57BL; Microglia; Middle Aged; Neuroprotective Agents; Parkinson Disease; Tumor Necrosis Factor-alpha | 2016 |
Co-treatment with natural HMGB1 inhibitor Glycyrrhizin exerts neuroprotection and reverses Parkinson's disease like pathology in Zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Glycyrrhizic Acid; HMGB1 Protein; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Neuroprotection; Neuroprotective Agents; Parkinson Disease; RNA, Messenger; Zebrafish | 2022 |